Skip to main content

Advertisement

Table 3 Histoclinical comparison of the two basal subgroups defined with the immune metagene in the independent validation series

From: Kinome expression profiling and prognosis of basal breast cancers

Characteristics (N) Immune-High n = 122 Immune-Low n = 396 p-value OR (95%CI)
  N (% of evaluated cases)    
Age (372)    0.71*  
≤ 50 years 53 (62%) 169 (59%)   1
> 50 years 33 (38%) 117 (41%)   1.11 (0.66-1.89)
Pathological tumor size, pT (394)    0.11*  
pT1 32 (33%) 73 (24%)   1
pT2-4 64 (67%) 225 (76%)   1.54 (0.9-2.6)
Pathological lymph node status, pN (420)    0.90*  
negative 62 (65%) 208 (64%)   1
positive 33 (35%) 117 (36%)   1.06 (0.64-1.77)
Tumor grade (420)    ND  
SBR 1 0 (0%) 13 (4%)   
SBR 2-3 103 (100%) 304 (96%)   
IHC ER status (434)    0.57*  
negative 73 (77%) 269 (79%)   1
positive 22 (23%) 70 (21%)   0.86 (0.49-1.57)
Lymphocyte infiltrate (56)    0.51*  
absent 6 (46%) 14 (33%)   1
present 7 (54%) 29 (67%)   1.76 (0.41-7.48)
Adjuvant chemotherapy (354)    0.43*  
no 49 (64%) 162 (58%)   1
yes 28 (36%) 115 (42%)   1.24 (0.72-2.18)
Adjuvant hormone therapy (269)    0.11*  
no 59 (91%) 197 (97%)   1
yes 6 (9%) 7 (3%)   0.40 (0.12-1.46)
Follow-up (months, median) (380) 95 89 0.44**  
Relapses (380) 25 (26.3%) 133 (46.7%) 4.77 E-04* 0.41 (0.23-0.70)
5-year DFS (380) 78% 54% 1.6 E-04***  
  1. N, number of tumor samples - out of the 2515 samples - with available information for the corresponding characteristic, *, Fisher's exact test; **, Mann-Whitney test; ***, log-rank test; ND, not done.